P149 Evaluating outcomes for patients with systemic lupus erythematosus treated with obinutuzumab, a humanised anti-CD20 monoclonal antibody, following secondary non-depletion of B cells and non-response with rituximab
Sign Up to like & getrecommendations! Published in 2025 at "Rheumatology"
DOI: 10.1093/rheumatology/keaf142.189
Abstract: We looked at outcomes for nine SLE patients treated at University College London Hospitals (UCLH) with obinutuzumab, a humanised anti-CD20 mAb, between January 2020 and October 2023. Patients previously failed rituximab for intolerance and/or secondary… read more here.
Keywords: treatment; non depletion; anti cd20; none ... See more keywords